the product in the database has an inactive status
indications:
Prevention of influenza, especially in patients with an increased risk of complications.
Composition:
1 dose (0.5 ml) contains purified influenza A and B influenza antigens, purified, split and inactivated (the vaccine complies with the WHO recommendation and the EU decision for the current season).
Action:
Inactivated influenza vaccine. Immunity is achieved after 2-3 weeks and is usually maintained for 6-12 months. The vaccine does not contain preservatives.
Contraindications:
Hypersensitivity to active substances, excipients or residues after the production process (chicken protein, polymyxin B). Vaccination should be postponed in patients with acute infection or febrile illness.
Precautions:
Pregnancy and lactation:
Previous studies in humans are insufficient to assess the effect of teratogenic and toxic effects on the fetus during pregnancy. In pregnant women, the possible risk of the disease should be considered in comparison with the risk associated with the administration of the vaccine. The vaccine can be used during breast-feeding.
Side effects:
The most common are: local reactions (redness, pain, swelling, ecchymosis, induration, in rare cases enlargement of the surrounding lymph nodes was observed) and general reactions (fever, malaise, chills, fatigue, headache, sweating, muscle pain, joint pain). Most often they disappear spontaneously after 1-2 days after vaccination. Rarely observed: neuralgia, paresthesia, convulsions, transient thrombocytopenia. In very rare cases vasculitis with transient changes in the kidneys has been observed. Rarely, neurological disorders may occur: encephalomyelitis, neuritis and Guillain, Barry and Strohl syndrome. Occasionally, allergic reactions occur, in very rare cases undergoing anaphylactic shock (for this reason, vaccinated people need to be observed for at least 30 minutes after vaccination). Administration of the vaccine may give false positive serological tests for antibodies against viruses: HIV1, hepatitis C and HTLV1 by ELISA. The Western Blot testing technique determines the correctness of tests.
Dosage:
Intramuscularly or deeply subcutaneously. Adults and children over 12 years of age: 1 dose of 0.5 ml. Children 4-12 years - 1 dose 0.5 ml; in children who have not received any doses of influenza vaccine in the last 4 years, 2 doses of 0.5 ml are required with an interval of at least 4 weeks. Children from 6 months of age up to 3 years - 2 doses of 0.25 ml (at least 4 weeks between doses of the vaccine should be kept).
(C)
